Overview

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Status:
Enrolling by invitation
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
Phase:
Phase 2
Details
Lead Sponsor:
Crinetics Pharmaceuticals Inc.